After Hours Summary: SNDX -16.3%, BMEA +6.6%, NVTS +4.7%, INCY -3.9%, FORM +2.3%, CYTK -1.5%, SVRA +1.2%
After Hours Gainers:
Companies trading higher in after hours in reaction to news:BMEA +6.6% (Will release Phase I GLP-131 results for oral GLP-1 receptor agonist BMF-650 on Oct. 13.), NVTS +4.7% (Developed a 24 kW 800V-to-12V AI power board with NVIDIA for its MGX ecosystem.), FORM +2.3% (Entered a semiconductor test collaboration with Teradyne, which agreed to invest $300 million in common stock.), SVRA +1.2% (Will present new IMPALA analysis and long-term Phase 3 molgramostim efficacy and safety data at CHEST 2026.)
After Hours Losers:
Companies trading lower in after hours in reaction to news:SNDX -16.3% (Phase 2 axatilimab trial in idiopathic pulmonary fibrosis missed its primary endpoint, prompting termination of IPF development.), INCY -3.9% (Partner Syndax’s Phase 2 axatilimab IPF trial missed its primary endpoint, ending further development in the indication.), CYTK -1.5% (Reported sub-50% LVEF in 10.5% of aficamten patients versus 0.8% on placebo in ACACIA-HCM.)